Relapsed or Refractory Lymphoid Malignancies
2
Pipeline Programs
3
Companies
3
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Baili PharmaceuticalBL-M08D1
Baili PharmaceuticalBL-M08D1
Mereo BioPharmaOMP-52M51
Clinical Trials (3)
Total enrollment: 68 patients across 3 trials
A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Start: Feb 2025Est. completion: Jun 202722 patients
Phase 1Recruiting
A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies
Start: Jan 2025Est. completion: Dec 202722 patients
Phase 1Recruiting
A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
Start: Oct 2012Est. completion: Jan 201624 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 68 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.